Sage Therapeutics drug for rare condition deemed a failure, but company may see a path forward

Sage Therapeutics Inc. shares plummeted 13.7% in Tuesday trade after the company said its brexanolone treatment missed primary and secondary endpoints in a late-stage clinical trial.

By most accounts, the trial was a failure. But the true disappointment is that the drug won’t be able to help patients with the seizure disorder super-refractory status epilepticus (SRSE) — there is currently no U.S. drug approved for the condition — said Sage SAGE, -13.69% CEO Jeff Jonas, and the trial may well prove to aid advances in SRSE therapies.

“The risk of being a pioneer is sometimes you get shot by the Indian,” Jonas said.

>>> Original Source <<<